{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:35:18Z","timestamp":1792852518758,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival (OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      6%; hazard ratio [HR], 0.74 [95% CI, 0.62 to 0.88]); similar benefit was observed regardless of tumor histology. Of biomarker-evaluable patients treated with nivolumab plus ipilimumab (n = 242), high baseline monocytic myeloid-derived suppressor cell (M-MDSC) levels correlated with worse OS versus low M-MDSC levels (HR, 1.25 [95% CI, 1.09 to 1.43]). After adjusting for 24% of patients in the chemotherapy arm who received subsequent immunotherapy, nivolumab plus ipilimumab demonstrated continued OS benefit versus chemotherapy (HR, 0.64 [95% CI, 0.53 to 0.78]). No new safety signals were observed. These results demonstrate long-term, durable clinical benefit with nivolumab plus ipilimumab versus chemotherapy, which continued to be preserved even after treatment-switching adjustment in the chemotherapy arm. Exploratory analyses suggested greater benefit with nivolumab plus ipilimumab in the low M-MDSC subgroup. These results further support first-line nivolumab plus ipilimumab as standard of care for unresectable PM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-01328","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:00:10Z","timestamp":1771966810000},"page":"742-749","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":9,"title":["Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct02899299","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-1863","authenticated-orcid":true,"given":"Arnaud","family":"Scherpereel","sequence":"first","affiliation":[{"name":"University of Lille, CHU Lille, INSERM U1189 OncoThAI, ONCOLille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-9556","authenticated-orcid":true,"given":"Paul","family":"Baas","sequence":"additional","affiliation":[{"name":"The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-9526","authenticated-orcid":true,"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[{"name":"University of Western Australia, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-6639","authenticated-orcid":true,"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Okayama Rosai Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":true,"given":"Solange","family":"Peters","sequence":"additional","affiliation":[{"name":"Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":true,"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":true,"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Bautista Aragon","sequence":"additional","affiliation":[{"name":"Centro M\u00e9dico Nacional Siglo XXI, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Talbot","sequence":"additional","affiliation":[{"name":"The Sunrise Centre, Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-3136","authenticated-orcid":true,"given":"Francesco","family":"Grossi","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, IRCCS Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-3229","authenticated-orcid":true,"given":"Dariusz","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet A.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Dicle University, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-4126","authenticated-orcid":true,"given":"Andr\u00e9s Felipe","family":"Cardona","sequence":"additional","affiliation":[{"name":"Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogot\u00e1, Colombia"},{"name":"Universidad El Bosque, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheela","family":"Soomro","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-1296","authenticated-orcid":true,"given":"Adam","family":"Lee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Uxbridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ip","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-3201","authenticated-orcid":true,"given":"Yu-Han","family":"Hung","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0343-9575","authenticated-orcid":true,"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Bichat-Claude Bernard Hospital, Thoracic Oncology Department, AP-HP. Nord Cancer Institute, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.076"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"e_1_3_11_6_2","unstructured":"OPDIVO (nivolumab) prescribing information. 2024. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"e_1_3_11_7_2","unstructured":"OPDIVO (nivolumab) summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.077"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30462-9"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01613-6"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.014"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030503"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-19-485"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081761"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.029"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866561"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100865"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0070-T"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.05.010"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3736"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00471-X"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.06.017"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02425"}],"updated-by":[{"DOI":"10.1200\/jco-26-01289","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000}},{"DOI":"10.1200\/jco-26-02181","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:59:08Z","timestamp":1788983948000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,3,20]]}},"alternative-id":["10.1200\/JCO-25-01328"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01328","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}